Collegium Pharmaceutical Inc. (COLL)
Best Value Stocks to Buy for Dec. 18
KE, COLL and JRVR made it to the Zacks Rank #1 (Strong Buy) value stocks list on Dec. 18, 2025.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run?
Collegium Pharmaceutical (COLL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Collegium Pharmaceutical: Another Solid Quarter
Collegium Pharmaceutical, Inc. just delivered standout Q3 results, with EPS and revenue significantly surpassing expectations, driving a 15% stock surge. COLL focuses on pain management treatments and expanded into ADHD with the recent Jornay PM acquisition, strengthening its product portfolio. Despite insider selling and a notable short interest, COLL maintains a strong cash position and manageable long-term debt.
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.88 per share. This compares to earnings of $1.61 per share a year ago.
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Collegium Pharmaceutical (COLL) Rating Upgrade to Strong Buy
Collegium Pharmaceutical (COLL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Vikram Karnani - CEO, President, Executive VP & Director Scott Dreyer - Executive VP & Chief Commercial Officer Colleen Tupper - Executive VP & CFO Conference Call Participants Robert Klingenberger Presentation Robert Klingenberger Good afternoon, everyone. My name is Bob Klingenberger.
Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Colleen Tupper - Executive VP & CFO Ian Karp - Corporate Participant Scott Dreyer - Executive VP & Chief Commercial Officer Vikram Karnani - CEO, President, Executive VP & Director Conference Call Participants David A. Amsellem - Piper Sandler & Co., Research Division John Todaro - Needham & Company, LLC, Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Operator Greetings, and welcome to the Collegium Pharmaceuticals Second Quarter 2025 Earnings Conference Call.
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.62 per share a year ago.
